#XBB.1.5 monovalent #vaccine induces lasting cross-reactive responses to #SARS-CoV-2 #variants such as HV.1 and #JN1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific #antibodies, https://etidiohnew.blogspot.com/2025/03/xbb15-monovalent-vaccine-induces.html
#XBB
Evolving #antibody #response to #SARS-CoV-2 #antigenic #shift from #XBB to #JN1
Source: Nature, AbstractThe continuous evolution of SARS-CoV-2, particularly the emergence of BA.2.86/JN.1 lineage replacing XBB, necessitates re-evaluation of vaccine compositions 1–3. Here, we provide a comprehensive analysis of the humoral immune response to XBB and JN.1 human exposure. We demonstrate the antigenic distinctiveness of XBB and JN.1 lineages in SARS-CoV-2-naive individuals,…
Effect of wild-type #vaccine doses on #BA5 hybrid #immunity, disease #severity, and #XBB #reinfection risk
Source: Journal of Virology, ABSTRACTVaccination against the wild-type (WT) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus did not produce detectable levels of neutralizing antibodies (NAbs) against the BA.5 strain before it emerged. However, coronavirus disease-2019 (COVID-19) severity varied highly between unvaccinated, partially vaccinated,…
#Clinical #profile analysis of #SARS-CoV-2 #community #infections during periods with #omicron #BA2, #BA4/5, and #XBB dominance in #HK: a prospective cohort study
Source: Lancet Infectious Diseases, SummaryBackgroundExisting studies on SARS-CoV-2 infection have mainly focused on severe clinical outcomes; understanding of the clinical severity profile of general community infections is poor. We aimed to assess and compare the clinical profiles of infections with…
[Correspondence] Virological #characteristics of the #SARS-CoV-2 #KP311 #variant https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00505-X/fulltext?rss=yes
SARS-CoV-2 #JN1 variant (#BA28611), arising from BA.2.86.1 with spike protein (S) substitution S:L455S, outcompeted previously predominant #XBB lineages by beginning of 2024. Subsequently, JN.1 subvariants including #KP2 (JN.1.11.1.2) & #KP3 (JN.1.11.1.3), which acquired additional S substitutions (eg, S:R346T, S:F456L, and S:Q493E) have emerged concurrently (appendix pp 19–20).2
A trivalent #protein-based pan- #Betacoronavirus #vaccine elicits cross-neutralizing #antibodies against a panel of coronavirus #pseudoviruses https://www.nature.com/articles/s41541-024-00924-x
We demonstrated broad neutralization by a trivalent subunit vaccine, formulating the receptor-binding domains of #SARS-CoV, #MERS-CoV, and SARS-CoV-2 #XBB.1.5 with Alum and CpG55.2.
Honestly, I HAVE HAD IT WITH THESE SO-CALLED “EXPERTS”
He lies and claims #Novavax will not be updating their vaccine from #xbb because they can’t get their shit together for #FLiRT (ad lib me)
People listen to this guy because he’s boring, ie “stable” sounding & therefore smart🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄🙄
If you didn’t fall into a Twitter🐰🕳️in 2022, you’d have no idea the danger
Ironically, there’s a focus on aging🤦🏻♀️ but not linking it to Covid?
ARE YOU F-ING KIDDING ME🤦🏻♀️
Great summary thread from the bird place by TR Gregory, that sums up important mutations from last year and into the potential future.
https://threadreaderapp.com/thread/1804870573010387245.html
#COVID
#CovidIsNotOver
#covid19
#XBB #JN1 #KP2 #KP3
#LB1 #FLiRT
Profiling #SARS-CoV-2-specific #Tcell response, Lancet Infect Dis. {Correspondence}, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00377-3/fulltext?rss=yes
#Omicron subvariants that escape #antibody-mediated neutralisation are still recognised by cross-reactive T-cells, & should not be considered antigenically distinct by definition. Vaccination with a monovalent #XBB.1.5 vaccine boosted T-cell responses, including T cells that were cross-reactive with #variants that emerged after XBB.1.5.
A reminder as #SARS-CoV-2 increases in wastewater in #BC: you can walk-in for a FREE #vaccine, and the #XBB.1.5 boosters confer some protection against infection from current variants.
No need to go through the awkward online booking system!
(Avoid Shopper's Drug Mart if possible, as they turn people away for the stupidest of reasons)
#BC #vaccines #SARSCoV2 #SARS2 #CovidIsNotOver #COVID #COVID19 #maskup
So I definitely was vaccinated
My gf & her family of Novids had their 2nd #XBB #Covid booster 6 months after their first & prior had 2 #Novavax old formulation & Pfizer prior to all that. They were all not free of side effects & it hit them hard relative to nothing happening prior
For myself, happened 🌡️check realizing that🌡️was ordered for more than checking🚰for yeast😂 & caught 100 degree but barely noticeable which must explain all the #asymptomatic people
Back to💯today
No excuses to lounge😇
#XBB15 monovalent #mRNA #vaccine #booster elicits robust neutralizing #antibodies against #XBB subvariants and #JN1, Cell Host Microbe: https://doi.org/10.1016/j.chom.2024.01.014
• An XBB.1.5 booster markedly enhanced neutralization of SARS-CoV-2, including JN.1
• An XBB.1.5 booster induced similar antibody titers to XBB infection
• Omicron infection followed by XBB.1.5 booster yielded the highest antibody titers
• Our findings supported recommendations for broad use of the updated XBB.1.5 booster
-- Updated monovalent #COVID19 #vaccines provided 54% (95% CI = 46–60%) #protection vs symptomatic #SARS-CoV-2 #infection in persons recently vaccinated compared w/ those who did not receive an updated dose. Vaccination provided protection for infections caused by #JN1 & infections caused by #XBB-related lineages. Waning of effectiveness is expected with additional elapsed time since vaccination, especially against less severe disease.
Convergent #evolution of #SARS-CoV-2 #XBB #lineages on #RBD 455–456 synergistically enhances #antibody #evasion and #ACE2 binding https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011868
Wirksamkeit der Boosterimpfung gegen #Corona nun nachgewiesen: >>Eine Studie der Klinik für Rheumatologie und Immunologie der Medizinischen Hochschule Hannover (MHH) schließt nun diese Lücke. In Kooperation mit dem MHH-Institut für Immunologie und dem Deutschen Primatenzentrum Göttingen haben die Forschenden die weltweit erste Publikation über den neuen #XBB.1.5 basierten Impfstoff von Biontech veröffentlicht. Im Rahmen der „#COVID-19 Contact (CoCo)“-Studie der MHH wurden 53 MHH-Beschäftigte untersucht, die den #Impfstoff erhalten haben. Anschließend wurde deren Immunreaktion gemessen. Das Ergebnis: Nach der #Impfung mit dem neuen #Booster waren die Antikörper gegen #Omikron #Varianten deutlich angestiegen. Die Arbeit ist in der renommierten Fachzeitschrift „The Lancet Infection Diseases“ veröffentlicht worden. [.. ]
„Wir haben nicht nur eine große Menge neutralisierender Antikörper gegen Omikron XBB.1.5 gefunden, sondern auch gegen andere #Unter-Varianten“, sagt die Oberärztin Professorin Dr. Alexandra Dopfer-Jablonka, die gemeinsam mit ihrem Klinikkollegen Professor Dr. Georg Behrens die Immunstudie leitet. Das bedeutet, der Impfstoff ruft die Immunabwehr nicht nur gegen die aktuell dominierende Corona-Variante XBB.1.5 auf den Plan, sondern aktiviert die körpereigene Abwehr auch gegen die sich gerade ausbreitende Varianten „#Pirola“ (#BA2.86) und „#Eris“ (#EG1.5). „Die #B-Zellen, die Antikörper gegen Omikron produzieren, wurden signifikant mehr und auch die #T-Zellen wurden durch die Impfung gestärkt“, erklärt die Rheumatologin. „Die Daten zeigen, dass die neue #Booster-Impfung ihr Ziel erreicht und darüber hinaus auch Antikörper gegen neue #SARS-CoV-2 Varianten induziert.“ [..] Eine #Auffrischungsimpfung mit dem neuen, angepassten Impfstoff ist laut Ständiger Impfkommission (#Stiko) für alle empfehlenswert, die 60 Jahre oder älter sind. Zudem sollten sich alle Menschen boostern lassen, die wegen einer #Grunderkrankung ein besonderes Risiko für einen schweren Krankheitsverlauf haben. Außerdem empfiehlt die Stiko die Auffrischungsimpfung für Bewohnerinnen und Bewohner von #Pflegeheimen sowie für# Beschäftigte im Pflege- und Gesundheitsbereich. Die Auffrischungsimpfung sollte jährlich wiederholt werden, vorzugsweise im Herbst. << https://idw-online.de/de/news826159
Why #Covid is still flooring some people #bbc
https://www.bbc.com/news/health-67726685
how about talking about how it damages #tcells instead of dated info from some immunology book back from when you were in Med school🙄
it👏🏼is👏🏼called👏🏼a👏🏼novel👏🏼virus👏🏼… for a reason!!!
also reasoning of not vaccinating #xbb for those under 65 to lessen burden on #nhs … 😶…😶😶😶😶😶🤯
Do these people hear themselves?🤦🏻♀️
I’m not dumb, ditzy on occasion but I get things eventually, however I read & see things constantly that are making me second guess myself; maddening
Prof Openshaw said: "The #viruses circulating now are pretty distant immunologically from the original #virus which was used to make the early #vaccines, or which last infected them.
"A lot of people have very little immunity to the #Omicron viruses and their #variants ."
WTF #misinformation is this?!?!
THERE IS NO NOR HAS THERE EVER BEEN DURABLE IMMUNITY TO A VIRUS THAT HAS MUTATED MORE IN 3 YEARS THAN FLU IN 15+++++ YEARS even if you were just infected
I just cannot🤦🏻♀️🤦🏻♀️🤦🏻♀️🤦🏻♀️🤦🏻♀️🤦🏻♀️
I’m a mean mean person for laughing hilariously at my husband’s #novavax #xbb reaction🤣🤷🏻♀️but it’s because I know it’s indicative of an immune response. Other 3 Novavax there was zero anything
Also in 16 years aside from #pfizer which got him violently flu like shakes ill, never seen him w/nary a cold
Tbh what he has, heavy head “like he was drinking alcohol all night”, headache & less pep in his step is hardly what I’d call a side effect. He felt bad enough to sleep more than usual & demanded 🐓🍲jokingly upon waking😂but nothing compared to #mRNA
[Correspondence] #Neutralisation activity of mucosal #IgA against #XBB sublineages and #BA286 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00732-6/fulltext?rss=yes
Got my #Phizer a few weeks back. Had #Novavax in May. Too bad PHAC took so long to approve Novavax this time around... But at least finally it has been approved for use in Canada, for #xbb and its variants...
https://www.cbc.ca/news/health/novavax-nuvaxovid-covid-19-vaccine-1.7049757
Client Info
Server: https://mastodon.social
Version: 2025.04
Repository: https://github.com/cyevgeniy/lmst